<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR33">
 <label>33.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Tepper</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Ashina</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Reuter</surname>
    <given-names>U</given-names>
   </name>
   <name>
    <surname>Brandes</surname>
    <given-names>JL</given-names>
   </name>
   <name>
    <surname>Dolezil</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Silberstein</surname>
    <given-names>S</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial</article-title>
  <source>Lancet Neurol</source>
  <year>2017</year>
  <volume>16</volume>
  <fpage>425</fpage>
  <lpage>434</lpage>
  <pub-id pub-id-type="doi">10.1016/S1474-4422(17)30083-2</pub-id>
  <?supplied-pmid 28460892?>
  <pub-id pub-id-type="pmid">28460892</pub-id>
 </element-citation>
</ref>
